Overview

The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy

Status:
Recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
This study is to investigate whether the alternating use of Prolia (Denosumab) and Aclasta (Zoledronic acid) can continue to increase bone density.
Phase:
Phase 4
Details
Lead Sponsor:
National Taiwan University Hospital
Treatments:
Denosumab
Zoledronic Acid